JP2022513729A - ヒト化及び親和性成熟抗ｃｅａｃａｍ１抗体 - Google Patents

ヒト化及び親和性成熟抗ｃｅａｃａｍ１抗体 Download PDF

Info

Publication number
JP2022513729A
JP2022513729A JP2021532041A JP2021532041A JP2022513729A JP 2022513729 A JP2022513729 A JP 2022513729A JP 2021532041 A JP2021532041 A JP 2021532041A JP 2021532041 A JP2021532041 A JP 2021532041A JP 2022513729 A JP2022513729 A JP 2022513729A
Authority
JP
Japan
Prior art keywords
antibody
antigen
sequence
binding fragment
ceacam1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021532041A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513729A5 (https=
Inventor
エス．ブランバーグ リチャード
ファン ユ－ファ
ガンディー アミット
ベルタグノリ モニカ
ユン チャールズ
ジョージ エドワード ホールゲイト ロバート
ロバート ハーン アーロン
ダーナ ジョーンズ スーザン
Original Assignee
ザ ブリガム アンド ウィメンズ ホスピタル，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ブリガム アンド ウィメンズ ホスピタル，インコーポレイティド filed Critical ザ ブリガム アンド ウィメンズ ホスピタル，インコーポレイティド
Publication of JP2022513729A publication Critical patent/JP2022513729A/ja
Publication of JP2022513729A5 publication Critical patent/JP2022513729A5/ja
Priority to JP2024177850A priority Critical patent/JP2025016505A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2021532041A 2018-12-07 2019-12-09 ヒト化及び親和性成熟抗ｃｅａｃａｍ１抗体 Withdrawn JP2022513729A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024177850A JP2025016505A (ja) 2018-12-07 2024-10-10 ヒト化及び親和性成熟抗ｃｅａｃａｍ１抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862776877P 2018-12-07 2018-12-07
US62/776,877 2018-12-07
PCT/US2019/065212 WO2020118295A1 (en) 2018-12-07 2019-12-09 Humanized and affinity-matured anti-ceacam1 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024177850A Division JP2025016505A (ja) 2018-12-07 2024-10-10 ヒト化及び親和性成熟抗ｃｅａｃａｍ１抗体

Publications (2)

Publication Number Publication Date
JP2022513729A true JP2022513729A (ja) 2022-02-09
JP2022513729A5 JP2022513729A5 (https=) 2022-12-19

Family

ID=70973892

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021532041A Withdrawn JP2022513729A (ja) 2018-12-07 2019-12-09 ヒト化及び親和性成熟抗ｃｅａｃａｍ１抗体
JP2024177850A Pending JP2025016505A (ja) 2018-12-07 2024-10-10 ヒト化及び親和性成熟抗ｃｅａｃａｍ１抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024177850A Pending JP2025016505A (ja) 2018-12-07 2024-10-10 ヒト化及び親和性成熟抗ｃｅａｃａｍ１抗体

Country Status (7)

Country Link
US (2) US12173066B2 (https=)
EP (1) EP3906261A4 (https=)
JP (2) JP2022513729A (https=)
CN (2) CN120209144A (https=)
AU (1) AU2019393077A1 (https=)
CA (1) CA3121580A1 (https=)
WO (1) WO2020118295A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025016505A (ja) * 2018-12-07 2025-02-04 ザ ブリガム アンド ウィメンズ ホスピタル，インコーポレイティド ヒト化及び親和性成熟抗ｃｅａｃａｍ１抗体

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202100033002A1 (it) * 2021-12-29 2023-06-29 Diatheva S R L Anticorpi umani e loro usi
US20250154251A1 (en) * 2022-02-03 2025-05-15 The Brigham And Women's Hospital, Inc. Companion diagnostic for human ceacam1 directed therapeutic agents
WO2024213096A1 (en) * 2023-04-13 2024-10-17 Suzhou Neologics Bioscience Co., Ltd. Ceacam1-targeting antibodies and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180153986A1 (en) * 2015-04-24 2018-06-07 The Brigham And Women's Hospital, Inc. Interactions between ceacam and tim family members

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180077322A (ko) * 2009-04-30 2018-07-06 텔 하쇼머 메디컬 리서치 인프라스트럭쳐 앤드 서비시스 리미티드． 항-ｃｅａｃａｍ1 항체들과 이를 이용하는 방법들
RU2012153241A (ru) * 2010-05-11 2014-06-20 Авео Фармасьютикалз, Инк. Антитела к fgfr2
WO2013054320A1 (en) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
US9556271B2 (en) * 2011-12-01 2017-01-31 The Brigham And Women's Hospital, Inc. Anti-CEACAM1 recombinant antibodies for cancer therapy
PL3763387T3 (pl) * 2013-11-25 2024-07-29 Famewave Ltd Kompozycje zawierające przeciwciała anty-ceacam1 i anty-pd do terapii nowotworu
US10550196B2 (en) 2014-04-27 2020-02-04 Famewave Ltd. Humanized antibodies against CEACAM1
WO2016120331A1 (de) * 2015-01-28 2016-08-04 Karl Sebastian Lang Agonistische anti-cd66cd66 antikörper für die antiviralen therapie
CN110475788A (zh) * 2017-03-24 2019-11-19 财团法人牧岩生命科学研究所 抗ceacam1抗体及其应用
EP3906261A4 (en) * 2018-12-07 2022-12-21 The Brigham And Women's Hospital, Inc. HUMANIZED AND AFFINITY MATURED ANTI-CEACAM1 ANTIBODIES

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180153986A1 (en) * 2015-04-24 2018-06-07 The Brigham And Women's Hospital, Inc. Interactions between ceacam and tim family members

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
岡山医学会雑誌, vol. 第121巻, JPN6022001530, 2009, pages 119 - 122, ISSN: 0005211360 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025016505A (ja) * 2018-12-07 2025-02-04 ザ ブリガム アンド ウィメンズ ホスピタル，インコーポレイティド ヒト化及び親和性成熟抗ｃｅａｃａｍ１抗体

Also Published As

Publication number Publication date
CN113840839A (zh) 2021-12-24
CA3121580A1 (en) 2020-06-11
US20220025040A1 (en) 2022-01-27
EP3906261A1 (en) 2021-11-10
CN113840839B (zh) 2025-02-14
WO2020118295A1 (en) 2020-06-11
US20250074980A1 (en) 2025-03-06
CN120209144A (zh) 2025-06-27
JP2025016505A (ja) 2025-02-04
EP3906261A4 (en) 2022-12-21
AU2019393077A1 (en) 2021-07-29
US12173066B2 (en) 2024-12-24

Similar Documents

Publication Publication Date Title
AU2016233495B2 (en) Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof
JP6286532B2 (ja) 抗ｃｄ３８抗体及び弱毒化インターフェロンアルファ−２ｂとの融合物
CN113929782B (zh) 对淋巴细胞中抑制途径的中和
JP2020036595A (ja) 抗ヒト４−１ｂｂ抗体およびその使用
JP2021511818A (ja) Ｖｉｓｔａ抗原結合性分子
KR20210008487A (ko) 항-cd24 조성물 및 이의 용도
CN110545845A (zh) 抗cd33抗体药剂
CN112778418A (zh) 对cd73具有特异性的结合分子及其用途
AU2019207767B2 (en) Novel combination and use of antibodies
US20250074980A1 (en) Humanized and Affinity-Matured Anti-CEACAM1 Antibodies
JP2022505925A (ja) 抗ｔｉｍ－３抗体
KR20240038043A (ko) 약학적 조성물 및 용도
WO2019242619A1 (zh) 全人源的抗lag-3抗体及其应用
TW202305005A (zh) 抗ｓｉｇｌｅｃ組合物及其用途
US20250388666A1 (en) Humanized and affinity-matured anti-ceacam1 antibodies and methods of use
US20250326849A1 (en) COMBINATION OF A FcyRIIB- AND A TUMOR ANTIBODY FOR USE IN THE TREATMENT OF AN FcyRIIB-NEGATIVE CANCER
TW202523694A (zh) 抗muc16抗體及其用途
HK40029838A (zh) 抗体的新型组合和用途
JP2018087218A (ja) 抗ｃｄ３８抗体及び弱毒化インターフェロンアルファ−２ｂとの融合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221209

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240430

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241010

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20241021

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20241108

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20241114